In the RADIATE (Rheumatoid Arthritis Study in Anti-TNF Failures) trial, Emery and colleagues [13] recently showed the improvement in 499 RA patients who had inadequate response to at least one anti-TNFα antagonist and who were treated with tocilizumab. The gene discussed is TNF; the disease is rheumatoid arthritis.